Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 3Melanoma 3Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Melanoma × sepantronium × Clear all
NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

NCT01009775 2015-09-04

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Astellas Pharma Inc

Phase 2 Completed
64 enrolled
Dermatologic

Melanoma

NCT00281541 2012-06-07

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Astellas Pharma Inc

Phase 2 Completed
29 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡